Core Insights - Bristol Myers Squibb and Johnson & Johnson have decided to discontinue the Phase 3 Librexia ACS trial due to an interim analysis indicating it is unlikely to meet the primary efficacy endpoint [1][3] - The safety profile of milvexian remains consistent with previous studies, with no new safety concerns identified [3] - Other trials in the Librexia program, including Librexia AF and Librexia STROKE, are recommended to continue as planned, with topline data expected in 2026 [4] Company Performance - Bristol Myers Squibb shares experienced a decline of 3.59%, trading at $46.88 at the time of publication [7] - The company has faced multiple late-stage trial setbacks, impacting investor sentiment and focus on upcoming data releases [6] Analyst Perspectives - Analysts view the discontinuation of the ACS trial as a modest negative signal for the Librexia STROKE study, given the shared dosing regimen of milvexian [5] - The AF indication is considered distinct with a larger market opportunity, as it evaluates a different dosing strategy [6]